Clovis Oncology Stock News

Shares of small-cap cancer company Clovis Oncology (NASDAQ: CLVS) gained a whopping 33.7% over the course of April, according to data from S&P; Global Market Intelligence. Clovis' stock regained it

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...

Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.

Q1 2020 Clovis Oncology Inc Earnings Call

Thank you for standing by, and welcome to the Clovis Oncology first-quarter 2020 financial results conference call. Then Dan Muehl, Clovis' chief financial officer, will cover the quarter's financial

Today's 5 Stock Ideas: * Sanofi (SNY) \- A play on a potential coronavirus vaccine. A report Tuesday evening suggested the company was in talks with several countries (including the US) related to adv

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

Clovis (CLVS) delivered earnings and revenue surprises of 0.78% and 1.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and commerci

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 5.) Arcturus Therapeutics Ltd (...

April turned out to be a productive month in terms of drug approvals, with the FDA issuing positive verdicts on almost all applications for which decisions were due. The month saw the approval of five

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Clovis Oncology (NASDAQ:CLVS) – Research analysts at SVB Leerink reduced their Q1 2020 EPS estimates for Clovis Oncology in a research note issued to investors on Monday, April 27th. SVB Leerink ana